Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Scand J Rheumatol ; 45(2): 107-13, 2016.
Article in English | MEDLINE | ID: mdl-26926492

ABSTRACT

OBJECTIVES: In systemic sclerosis (SSc)-related interstitial lung disease (ILD), elevated eosinophil counts in bronchoalveolar lavage are associated with a worse outcome. We hypothesized that eosinophils may be activated in the peripheral circulation, thereby increasing their recruitment to affected tissues and contributing to inflammation and fibrosis. The aim of this study was to characterize the blood eosinophils in SSc patients. METHOD: Expression levels of surface markers CD11b, CD44, CD48, CD54, CD69, CD81, and HLA-DR on CD16(low)CD9(high)-expressing eosinophils were measured by flow cytometry in whole blood from SSc patients (n = 32) and controls (n = 11). RESULTS: Expression levels of CD54, CD69, and HLA-DR were undetectable in all groups. CD44 and CD11b expression levels were similar between groups. CD81 expression was lower in patients compared to controls independent of disease duration (p = 0.001). CD48 expression was increased in patients with a short disease duration (< 2 years) compared to both controls (p = 0.042) and patients with longer disease duration (≥ 2 years; p = 0.027). In patients with short disease duration, increased CD48 expression was associated with alveolar inflammation as measured by an increased concentration of alveolar nitric oxide (r = 0.76, p = 0.003). CONCLUSIONS: Blood eosinophils change phenotype during disease evolution in SSc, and CD48 expression may be used as a biomarker for pulmonary inflammation.


Subject(s)
Antigens, CD/metabolism , Eosinophils/metabolism , Pulmonary Fibrosis/metabolism , Scleroderma, Systemic/metabolism , Tetraspanin 28/metabolism , Aged , Biomarkers , CD48 Antigen , Case-Control Studies , Flow Cytometry , Humans , Male , Middle Aged , Nitric Oxide/metabolism , Phenotype , Pulmonary Fibrosis/etiology , Scleroderma, Diffuse/metabolism , Scleroderma, Limited/metabolism , Scleroderma, Systemic/complications , Time Factors
2.
Clin Exp Immunol ; 176(3): 363-72, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24666336

ABSTRACT

Anti-neutrophil cytoplasmic antibodies (ANCA) are thought to be pathogenic in ANCA-associated vasculitis (AAV) by stimulating polymorphonuclear leucocytes (PMNs) to degranulate and produce reactive oxygen species (ROS). The aim of this study was to investigate if PMNs from AAV patients are stimulated more readily by ANCA compared with PMNs from healthy controls (HCs). Differences in ANCA characteristics that can account for different stimulation potential were also studied. PMNs from five AAV patients and five HCs were stimulated with 10 different immunoglobulins (Ig)Gs, purified from PR3-ANCA-positive patients, and ROS production, degranulation and neutrophil extracellular trap (NET) formation was measured. ANCA levels, affinity and clinical data of the AAV donors were recorded. The results show that PMNs from AAV patients produce more intracellular ROS (P = 0·019), but degranulate to a similar extent as PMNs from HCs. ROS production correlated with NET formation. Factors that may influence the ability of ANCA to activate PMNs include affinity and specificity for N-terminal epitopes. In conclusion, our results indicate that PMNs from AAV patients in remission behave quite similarly to HC PMNs, with the exception of a greater intracellular ROS production. This could contribute to more extensive NET formation and thus an increased exposure of the ANCA autoantigens to the immune system.


Subject(s)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/immunology , Antibodies, Antineutrophil Cytoplasmic/immunology , Neutrophils/immunology , Aged , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/metabolism , Cell Degranulation/immunology , Epitopes/immunology , Humans , Immunoglobulin G/immunology , Middle Aged , Neutrophils/metabolism , Reactive Oxygen Species/metabolism
3.
Clin Exp Immunol ; 170(1): 47-56, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22943200

ABSTRACT

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases, including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). It is not known why ANCA develop, but it has been shown that they participate in pathogenesis by activating polymorphonuclear neutrophils (PMNs). In this study we hypothesize that dysregulation of phagocytosis in AAV leads to the accumulation of apoptotic neutrophils seen in association with blood vessels in AAV. These cells progress into secondary necrosis, contributing to tissue damage and autoantibody formation. Peripheral blood cells were counted, and phagocytosis was investigated using monocyte-derived macrophages (MØ) and PMNs from healthy blood donors (HBD), AAV patients and systemic lupus erythematosus (SLE) patients. Furthermore, the effect of serum was assessed. Phagocytosis was measured using flow cytometry. The results showed no deviation in monocyte subpopulations for AAV patients compared to HBDs, although there was a decrease in lymphocyte and pDC (plasmacytoid dendritic cell) populations (4·2 × 10(6) cells/l versus 10·4 × 10(6) cells/l, P < 0·001). The number of neutrophils was increased (6·0 × 10(9) cells/l versus 3·8 × 10(9) cells/l, P < 0·001). There were no differences found in the ability of MØs to engulf apoptotic cells, nor when comparing apoptotic PMNs to become engulfed. However, serum from AAV donors tended to decrease the phagocytosis ability of MØs (36%) compared to serum from HBDs (43%). In conclusion, there is no intrinsic dysfunction in the MØs or in the PMNs that have an effect on phagocytic activity, but ANCA may play a role by decreasing phagocytic ability.


Subject(s)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/immunology , Antibodies, Antineutrophil Cytoplasmic/immunology , Apoptosis/immunology , Neutrophils/pathology , Phagocytosis/immunology , Adult , Aged , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/blood , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/pathology , Antibodies, Antineutrophil Cytoplasmic/metabolism , Case-Control Studies , Dendritic Cells/immunology , Dendritic Cells/pathology , Flow Cytometry , Humans , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/pathology , Lymphocytes/immunology , Lymphocytes/pathology , Macrophages/immunology , Macrophages/metabolism , Microscopic Polyangiitis/immunology , Microscopic Polyangiitis/pathology , Middle Aged , Necrosis/immunology , Neutrophils/immunology
4.
Clin Exp Immunol ; 161(1): 89-97, 2010 Jul 01.
Article in English | MEDLINE | ID: mdl-20491791

ABSTRACT

Proteinase 3 (PR3) is a major autoantigen in anti-neutrophil cytoplasmic antibodies (ANCA)-associated systemic vasculitis (AASV), and the proportion of neutrophils expressing PR3 on their membrane (mPR3+) is increased in AASV. We have shown recently that mPR3 and CD177 are expressed on the same cells in healthy individuals. In this study we try to elucidate mechanisms behind the increased mPR3 expression in AASV and its relationship to CD177. All neutrophils in all individuals were either double-positive or double-negative for mPR3 and CD177. The proportion of double-positive neutrophils was increased significantly in AASV and systemic lupus erythematosus patients. The proportion of mPR3+/CD177+ cells was not correlated to general inflammation, renal function, age, sex, drug treatment and levels of circulating PR3. AASV patients had normal levels of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Pro-PR3 was found to constitute 10% of circulating PR3 but none of the mPR3. We found increased mRNA levels of both PR3 and CD177 in AASV, but they did not correlate with the proportion of double-positive cells. In cells sorted based on membrane expression, CD177-mRNA was several-fold higher in mPR3+ cells. When exogenous PR3 was added to CD177-transfected U937 cells, only CD177+ cells bound PR3 to their membrane. In conclusion, the increased membrane expression of PR3 found in AASV is not linked directly to circulating PR3 or PR3 gene transcription, but is dependent upon CD177 expression and correlated with the transcription of the CD177 gene.


Subject(s)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/enzymology , Cell Membrane/metabolism , Isoantigens/physiology , Membrane Glycoproteins/physiology , Myeloblastin/biosynthesis , Neutrophils/enzymology , Receptors, Cell Surface/physiology , Adult , Aged , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/blood , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/immunology , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/enzymology , Arthritis, Rheumatoid/immunology , Blood Donors , Enzyme Induction , Female , GPI-Linked Proteins , Gene Expression Regulation , Granulocyte Colony-Stimulating Factor/blood , Granulocyte-Macrophage Colony-Stimulating Factor/blood , Hemoglobinuria, Paroxysmal/blood , Hemoglobinuria, Paroxysmal/enzymology , Hemoglobinuria, Paroxysmal/immunology , Humans , Isoantigens/biosynthesis , Isoantigens/genetics , Kidney Transplantation , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/enzymology , Lupus Erythematosus, Systemic/immunology , Male , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/genetics , Middle Aged , Myeloblastin/genetics , Myeloblastin/pharmacology , Neutrophils/immunology , RNA, Messenger/biosynthesis , RNA, Messenger/blood , Receptors, Cell Surface/biosynthesis , Receptors, Cell Surface/genetics , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics , Transcription, Genetic , U937 Cells/drug effects , U937 Cells/enzymology
5.
Clin Exp Immunol ; 160(3): 318-24, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20059480

ABSTRACT

Anti-neutrophil cytoplasmic antibodies against proteinase 3 (PR3-ANCA) are used as diagnostic tools for patients with small vessel vasculitis (AASV). We have produced chimeric mouse/human PR3 molecules and investigate changes in reactivity over time and the possible relationship between epitope specificity and clinical course. Thirty-eight PR3-ANCA-positive patients diagnosed between 1990 and 2003 were followed until December 2005. Plasma was collected at each out-patient visit and older samples were retrieved retrospectively. Patients reacted with multiple epitopes at the time of diagnosis. At subsequent relapses 12 patients shifted reactivity, in 11 cases from epitopes located in the C-terminal towards epitopes in the N-terminal. Patients with reactivity against N-terminal parts of PR3 at diagnosis had a significantly lower relapse rate, 30% compared to 78% in the group with predominantly C-terminal reactivity (P = 0.04). The reactivity pattern did not correlate to outcome measured as death, end-stage renal disease or vasculitis activity index score (VDI) at 5 years. Further research is necessary to conclude if this is a general phenomenon.


Subject(s)
Antibodies, Antineutrophil Cytoplasmic/immunology , Antibody Specificity/immunology , Autoimmune Diseases/immunology , Epitopes/immunology , Myeloblastin/immunology , Vasculitis/immunology , Adolescent , Adult , Aged , Antibodies, Antineutrophil Cytoplasmic/blood , Autoimmune Diseases/blood , Autoimmune Diseases/mortality , Autoimmune Diseases/therapy , Child , Epitopes/metabolism , Female , Humans , Male , Middle Aged , Myeloblastin/metabolism , Prospective Studies , Protein Structure, Tertiary , Retrospective Studies , Vasculitis/blood , Vasculitis/mortality , Vasculitis/therapy
6.
Clin Exp Immunol ; 145(1): 63-70, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16792675

ABSTRACT

Several findings link proteinase 3 (PR3) to small vessel vasculitis. Besides being a major target of anti-neutrophil cytoplasm antibodies (ANCA), previous findings have shown increased circulating levels of PR3 in vasculitis patients, increased levels of neutrophil membrane-PR3 (mPR3) expression and a skewed distribution of the - 564 A/G polymorphism in the promotor region of the PR3 gene. In this study we elucidate how these three findings relate to each other. The plasma concentration of PR3 was measured by enzyme-linked immunosorbent assay (ELISA), mPR3 expression by fluorescence activated cell sorter (FACS) and the gene polymorphism by real-time polymerase chain reaction (PCR). We compared results from 63 patients with ANCA-associated systemic vasculitis (AASV) with 107 healthy blood donors. In accordance with previous reports, AASV patients had increased plasma concentrations of PR3 compared to healthy controls (mean 224 microg/l versus 155 microg/l, P < 0.0001). They also showed an increased number of mPR3-positive neutrophils (60%versus 42%, P < 0.001). However, contrary to a previous report, we found no skewed distribution of the polymorphism in PR3 gene. There was a weak correlation between mPR3 mean fluorescence intensity (MFI) and plasma PR3 among healthy controls and myeloperoxidase-ANCA (MPO-ANCA)-positive patients (r = 0.24, P = 0.015 and r = 0.52, P = 0.011, respectively). In conclusion, increased plasma PR3 and high expression of mPR3 are associated with small vessel vasculitis, but neither of them is a consequence of the - 564 A/G polymorphism of the PR3 gene promotor.


Subject(s)
Neutrophils/enzymology , Serine Endopeptidases/analysis , Vasculitis/enzymology , Case-Control Studies , Cell Membrane/enzymology , Chi-Square Distribution , Flow Cytometry , Genotype , Humans , Myeloblastin , Phenotype , Polymorphism, Genetic , Promoter Regions, Genetic , Reverse Transcriptase Polymerase Chain Reaction , Serine Endopeptidases/blood , Serine Endopeptidases/genetics , Vasculitis/genetics
7.
Kidney Int ; 69(10): 1799-805, 2006 May.
Article in English | MEDLINE | ID: mdl-16557221

ABSTRACT

Myeloperoxidase (MPO) is one of the major target antigens of antineutrophil cytoplasmic autoantibodies (ANCA) found in patients with small-vessel vasculitis and pauci-immune necrotizing glomerulonephritis. To date, the target epitopes of MPO-ANCA remain poorly defined. Human MPO-ANCA do not typically bind mouse MPO. We utilized the differences between human and mouse MPO to identify the target regions of MPO-ANCA. We generated five chimeric MPO molecules in which we replaced different segments of the human or mouse molecules with their homologous counterpart from the other species. Of serum samples from 28 patients screened for this study, 43 samples from 14 patients with MPO-ANCA-associated vasculitis were tested against recombinant human and mouse MPO and the panel of chimeric molecules. Sera from 64 and 71% of patients bound to the carboxy-terminus of the heavy chain, in the regions of amino acids 517-667 or 668-745, respectively. No patient serum bound the MPO light chain or the amino-terminus of the heavy chain. All sera bound to only one or two regions of MPO. Although the pattern of MPO-ANCA binding changed over time (4-27 months) in 6 of 10 patients with several serum samples, such changes were infrequent. Other target regions of MPO-ANCA may not have been detected due to conformational differences between the native and recombinant forms of MPO. MPO-ANCA do not target a single epitope, but rather a small number of regions of MPO, primarily in the carboxy-terminus of the heavy chain.


Subject(s)
Antibodies, Antineutrophil Cytoplasmic/immunology , Epitope Mapping , Epitopes/analysis , Peroxidase/genetics , Peroxidase/immunology , Adult , Aged , Amino Acid Sequence , Animals , Antibodies, Antineutrophil Cytoplasmic/blood , Biomarkers/blood , Case-Control Studies , Female , Glomerulonephritis/blood , Glomerulonephritis/enzymology , Glomerulonephritis/immunology , Glomerulonephritis/physiopathology , Humans , Male , Mice , Middle Aged , Models, Molecular , Molecular Sequence Data , Peroxidase/blood , Peroxidase/chemistry , Protein Structure, Quaternary , Recombinant Proteins/blood , Recombinant Proteins/chemistry , Recombinant Proteins/immunology , Recombinant Proteins/isolation & purification , Sequence Homology, Amino Acid , Vasculitis/immunology
8.
Clin Exp Immunol ; 141(1): 174-82, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15958084

ABSTRACT

Proteinase 3 (PR3) is a pleiotropic and destructive serine protease and it is also a major target for autoantibodies in systemic small vessel vasculitis. We have shown recently that patients in stable remission have increased circulating levels of PR3, independent of autoantibody titre, inflammation, neutrophil degranulation and renal function. Here we explore the possibility of increased PR3 gene transcription. RNA was purified from peripheral blood monocytes from vasculitis patients and controls. Specific mRNA was measured by TaqMan real-time polymerase chain reaction (PCR). The monocyte-like cell lines THP-1 and U937 and human peripheral blod monocytes from healthy controls were stimulated with cytokines and lipopolysaccharide (LPS) for different time periods. PR3 protein was measured in plasma with enzyme-linked immunosorbent assay (ELISA). The median result for PR3 mRNA was 9.6 (1.8-680) for 22 patients, compared to 1 (0.1-2.8) for the 15 healthy controls. Elastase expression was also significantly increased, whereas myeloperoxidase and interleukin-8 were not. Stimulation of monocytes with tumour necrosis factor (TNF)-alpha, interferon (IFN)-gamma or LPS did not result in any increase of PR3 or elastase transcription, whereas interleukin (IL)-8 transcription was increased 10-fold. Circulating monocytes from patients with systemic vasculitis display increased PR3 gene transcription compared to healthy controls and patients with sytemic lupus erythematosus (SLE). This may be important for the development of vasculitis. Our results do not favour a role for cytokines, antineutrophil cytoplasmic antibodies (ANCA) or immunosuppressive medication in the upregulation of PR3 transcription in vasculitis.


Subject(s)
Monocytes/enzymology , Serine Endopeptidases/genetics , Transcription, Genetic , Vasculitis/genetics , Adult , Aged , Aged, 80 and over , Antibodies, Antineutrophil Cytoplasmic/blood , Cell Line, Tumor , Cytokines/pharmacology , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Interleukin-8/metabolism , Lupus Erythematosus, Systemic/enzymology , Lupus Erythematosus, Systemic/genetics , Male , Middle Aged , Myeloblastin , Peroxidase/blood , Polymerase Chain Reaction/methods , RNA, Messenger/genetics , Serine Endopeptidases/blood , Transcription, Genetic/drug effects , Up-Regulation , Vasculitis/enzymology
9.
Clin Exp Immunol ; 138(2): 266-70, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15498036

ABSTRACT

Proteinase 3 is the major autoantigen in patients with Wegener's granulomatosis. Earlier studies have shown that circulating leucocytes from patients with Wegener's granulomatosis show elevated proteinase 3 surface expression and mRNA levels. Wegener's granulomatosis patients also have increased levels of proteinase 3 in plasma. A single nucleotide polymorphism (SNP) (-564 A/G SNP) in the promoter region has been associated with disease. This SNP introduces a new potential Sp1 transcription factor binding site that may be responsible for the observed up-regulated expression of proteinase 3. To investigate this a 740 base pair long region of the promoter was cloned from genomic DNA. The disease-associated -564 A/G, as well as a control -621 A/G exchange, were introduced by polymerase chain reaction mutagenesis and cloned into a luciferase reporter vector. Endogenous expression levels of proteinase 3 mRNA and promoter activity of the cloned constructs were measured in three myeloid cell lines, HL-60, U937 and NB-4, and in epithelial HeLa cells. The results demonstrate a good correlation between the endogenous proteinase 3 mRNA expression and the promoter activity, as judged by luciferase activity. However, no significant differences in activity between the wild-type, polymorphic and the mutated control variant were found. In conclusion, the -564 A/G polymorphism is not responsible for the increased expression levels seen in myeloid cells from patients with Wegener's granulomatosis.


Subject(s)
Granulomatosis with Polyangiitis/genetics , Polymorphism, Single Nucleotide/genetics , Promoter Regions, Genetic/genetics , Serine Endopeptidases/genetics , Antibodies, Antineutrophil Cytoplasmic/genetics , Antibodies, Antineutrophil Cytoplasmic/immunology , Cell Line, Tumor , Granulomatosis with Polyangiitis/immunology , HL-60 Cells , HeLa Cells , Humans , Myeloblastin , Polymorphism, Single Nucleotide/immunology , Promoter Regions, Genetic/immunology , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction/methods , Serine Endopeptidases/immunology , Transcription, Genetic , Transfection/methods , U937 Cells
10.
Clin Exp Immunol ; 135(1): 164-72, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14678279

ABSTRACT

Autoantibodies against proteinase 3 (PR3) and myeloperoxidase (MPO) (ANCA = anti-neutrophil cytoplasmic antibodies) are used as diagnostic tools for patients with small vessel vasculitis. ANCA are detected by different assays, but the correlation between the results of these assays is generally poor. The overall aim of the study was to provide a framework for the future development of new assays with an increased diagnostic yield. In order to express discrete epitopes of human PR3 (hPR3), the nonantigenic molecules murine PR3 (mPR3) and human leucocyte elastase (HLE) were used as a framework. We constructed recombinant chimeric vectors and were able to produce 6 hPR3/mPR3 proteins and 3 hPR3/HLE proteins. Anti-PR3 monoclonal antibodies differed in their binding pattern to the chimeras, but no distinct binding region could be identified for any monoclonal antibody. The recombinant hPR3/mPR3 were also tested in ELISA with sera from patients with Wegener's granulomatosis with renal involvement. The results show that patients have antibodies to different constructs, indicating that the patients vary in their antibody repertoire from the beginning of the disease, and that patients may have antibodies from a broad range of clones early in the course of the disease. Recombinant hPR3/mPR3 chimeric proteins have a potential to be used as antigens in future ANCA assays.


Subject(s)
Antibodies, Antineutrophil Cytoplasmic/blood , Epitope Mapping/methods , Granulomatosis with Polyangiitis/diagnosis , Serine Endopeptidases/immunology , Amino Acid Sequence , Animals , Antibodies, Antineutrophil Cytoplasmic/immunology , Antibodies, Monoclonal/immunology , Autoantibodies/immunology , Cells, Cultured , Enzyme-Linked Immunosorbent Assay/methods , Genetic Vectors , Granulomatosis with Polyangiitis/immunology , Humans , Leukocyte Elastase/genetics , Mice , Molecular Sequence Data , Myeloblastin , Peroxidase/immunology , Recombinant Fusion Proteins/immunology , Recombinant Proteins/immunology , Serine Endopeptidases/genetics , Transfection
11.
J Biol Chem ; 275(40): 30844-8, 2000 Oct 06.
Article in English | MEDLINE | ID: mdl-10896942

ABSTRACT

Goodpasture disease fulfils all criteria for a classical autoimmune disease, where autoantibodies targeted against the non-collagenous domain of the alpha3-chain of collagen IV initiates an inflammatory destruction of the basement membrane in kidney glomeruli and lung alveoli. This leads to a rapidly progressive glomerulonephritis and severe pulmonary hemorrhage. Previous studies have indicated a limited epitope for the toxic antibodies in the N-terminal part of the non-collagenous domain. The epitope has been partially characterized by recreating the epitope in the non-reactive alpha1-chain by exchanging nine residues to the corresponding ones of alpha3. In this study we have investigated to what extent each of these amino acids contribute to the antibody binding in different patient sera. The results show that seven of the nine substitutions are enough to get an epitope that is recognized equally well as the native alpha3-chain by all sera from 20 clinically verified Goodpasture patients. Furthermore, the patient sera reactivity against the different recombinant chains used in the study are very similar, with some minor exceptions, strongly supporting a highly defined and restricted epitope. We are convinced that the restriction of the epitope is of significant importance for the understanding of the etiology of the disease. Thereby also making every step on the way to characterization of the epitope a crucial step on the way to specific therapy for the disease.


Subject(s)
Anti-Glomerular Basement Membrane Disease/genetics , Anti-Glomerular Basement Membrane Disease/immunology , Autoantigens/chemistry , Collagen Type IV , Collagen/chemistry , Adolescent , Adult , Aged , Amino Acid Sequence , Amino Acids/chemistry , Antibodies/metabolism , Cell Line , DNA, Complementary/metabolism , Dose-Response Relationship, Drug , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Epitopes , Female , Humans , Immunoblotting , Immunoglobulin G/immunology , Kinetics , Male , Middle Aged , Models, Genetic , Molecular Sequence Data , Mutagenesis, Site-Directed , Protein Structure, Secondary , Recombinant Proteins/chemistry , Recombinant Proteins/immunology , Sequence Homology, Amino Acid , Transfection
12.
J Biol Chem ; 274(36): 25862-8, 1999 Sep 03.
Article in English | MEDLINE | ID: mdl-10464328

ABSTRACT

Goodpasture disease is a prototype autoimmune disease characterized by the formation of autoantibodies against the heterotrimeric basement membrane collagen type IV, which causes a rapidly progressive glomerulonephritis. The pathogenic antibody response is directed to the non-collagenous (NC1) domain of the alpha3 chain of type IV collagen (alpha3(IV)NC1), but not to the homologous region of the alpha1(IV)NC1. To identify the conformation-dependent immunodominant epitope on the alpha3(IV)NC1, a variety of recombinant NC1 domains were constructed by replacing single residues of alpha3(IV) with the corresponding amino acids from the nonreactive alpha1(IV) chain. Replacement mutations were identified that completely destroyed the Goodpasture epitope in the alpha3(IV) chain. Based on the identification of these critical positions, the epitope was finally reconstructed within the frame of the alpha1(IV) chain. The substitution of nine discontinuous positions in the alpha1(IV)NC1 with amino acid residues from the alpha3 chain resulted in a recombinant construct that was recognized by all patients' sera (n = 20) but by none of the sera from healthy controls (n = 10). This provides, for the first time, the molecular characterization of a single immunodominant conformational epitope recognized by pathogenic autoantibodies in a human autoimmune disease, representing the basis for the development of new epitope-specific strategies in the treatment of Goodpasture disease.


Subject(s)
Anti-Glomerular Basement Membrane Disease/immunology , Autoantibodies/immunology , Collagen/immunology , Epitopes/immunology , Antibody Specificity , Cell Line , Collagen/chemistry , Epitope Mapping , Epitopes/chemistry , Humans , Mutation , Protein Conformation
13.
Kidney Int ; 55(3): 936-44, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10027930

ABSTRACT

BACKGROUND: The characteristic feature of Goodpasture disease is the occurrence of an autoantibody response to the noncollagenous domain of the alpha3 chain of type IV collagen [alpha3(IV)NC1] in the alveolar and glomerular basement membrane. These antibodies are associated with the development of a rapidly progressive glomerulonephritis, with or without lung hemorrhage, whereas autoantibodies specific for the other alpha chains of the heterotrimeric type IV collagen probably do not cause disease. In this study, we have investigated whether differences in fine specificity of autoimmune recognition of the alpha3(IV)NC1 correlate with clinical outcome. METHODS: For mapping of antibody binding to type IV collagen, chimeric collagen constructs were generated in which parts of the alpha3(IV)NC1 domain were replaced by the corresponding sequences of homologous nonreactive alpha1(IV). The different recombinant collagen chimeras allowed the analysis of antibody specificities in 77 sera from well-documented patients. RESULTS: One construct that harbors the aminoterminal third of the alpha3(IV)NC1 was recognized by all sera, indicating that it represents the dominant target of the B-cell response in Goodpasture disease. Seventy percent of the samples recognized other parts of the molecule as well. However, only reactivity to the N-terminus of the alpha3(IV)NC1 correlated with prognosis, that is, kidney survival after six months of follow-up. CONCLUSION: The results indicate the crucial importance of antibody recognition of this particular domain for the pathogenesis of Goodpasture disease, thereby opening new avenues for the development of better diagnostic and therapeutic procedures.


Subject(s)
Anti-Glomerular Basement Membrane Disease/genetics , Anti-Glomerular Basement Membrane Disease/immunology , Autoantigens/chemistry , Autoantigens/genetics , Collagen Type IV , Collagen/chemistry , Collagen/genetics , Immunodominant Epitopes/chemistry , Immunodominant Epitopes/genetics , Autoantibodies/blood , Base Sequence , Case-Control Studies , Cell Line , Cloning, Molecular , DNA Primers/genetics , Enzyme-Linked Immunosorbent Assay , Epitope Mapping , Humans , Prognosis , Protein Conformation , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Transfection
14.
Clin Exp Immunol ; 108(1): 167-74, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9097926

ABSTRACT

Interactions between plasma proteins and MPO were studied. The protein fraction of normal plasma and serum was shown to exhibit an inhibitory effect on the peroxidase activity of MPO. Most of the inhibitory effect could be retained on an MPO-coupled affinity chromatography column. In particular, a protein with apparent mol. wt of 130 kD showed affinity for MPO. The protein was identified as ceruloplasmin by N-terminal amino acid sequencing and immunochemistry. During separation procedures the peroxidase inhibitory effect was limited to ceruloplasmin-containing fractions of plasma. Purified ceruloplasmin inhibited the peroxidase activity of MPO in a concentration-dependent manner, and exhibited selective binding to MPO-coated microtitre plates. This binding could be inhibited by MPO dissolved in buffer. Correspondingly the binding of MPO to ceruloplasmin-coated plates could be blocked by ceruloplasmin in solution, showing a physical interaction to occur between the two proteins under physiological conditions. We also found affinity to exist between MPO and C3 (and its C3d-containing fragments). However, C3 and C3 fragments did not inhibit the peroxidase reaction in vitro. We propose that ceruloplasmin takes part in the clearance and inactivation of MPO, in vivo. We also speculate that impaired inactivation of MPO may have a pathophysiological role in inflammatory diseases characterized by autoantibodies to MPO, such as rapidly progressive glomerulonephritis with P-ANCA (perinuclear anti-neutrophil cytoplasmic antibodies).


Subject(s)
Ceruloplasmin/physiology , Peroxidase/antagonists & inhibitors , Ceruloplasmin/isolation & purification , Chromatography, Affinity , Humans , Immunoblotting , Peroxidase/metabolism , Protein Binding
16.
J Am Soc Nephrol ; 8(3): 376-85, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9071706

ABSTRACT

An appreciable percentage of patients with serum anti-glomerular basement membrane (anti-GBM) antibodies also have antineutrophil cytoplasmic antibodies (ANCA), against either myeloperoxidase (MPO-ANCA), or proteinase 3 (PR3-ANCA). In sera without ANCA, the anti-GBM antibodies have been shown to react mainly with the noncollagenous domain (NC1) of Type IV collagen, and especially with its alpha 3 chain, alpha 3(IV)NC1. In most sera, the antibodies can be partially blocked by a monoclonal antibody (Mab17) against alpha 3(IV)NC1, suggesting that a limited region is recognized. Although there is evidence that some anti-GBM antibodies that coexist with ANCA react with alpha 3(IV)NC1, extensive analysis of the specificity of such anti-GBM antibodies has not been reported. In the study presented here, sera were analyzed from 332 patients tested both for anti-GBM antibodies and ANCA (MPO or PR3-ANCA) and found to have one or more positive tests. Of the 100 sera with anti-GBM antibodies, 38 also had ANCA-25 with MPO-ANCA (66%), 12 with PR3-ANCA (32%), and one with both (2%). Of the 232 sera with ANCA only, 153 had MPO-ANCA (66%), 75 had PR3-ANCA (32%), and four had both (2%). Sera was also analyzed from 259 other patients who had positive ANCA tests and were not tested for anti-GBM antibodies: 138 had MPO-ANCA (54%), and 121 had PR3-ANCA (46%). The relative frequencies of MPO or PR3-ANCA in patients with coexisting anti-GBM antibodies did not differ significantly from those in all patients with ANCA (P = 0.35). Seventeen sera with anti-GBM antibodies only and 16 sera with anti-GBM antibodies plus ANCA were selected for further studies to compare the specificity of anti-GBM antibodies in sera with or without ANCA. Using enzyme-linked immunosorbent assays (ELISA), all sera in both groups were found to react with the NC1 domain (as a hexamer) of bovine Type IV collagen and with alpha 3 (IV)NC1 monomers. Furthermore, all but six sera also reacted with one or more of the alpha 1, 2, and 4 (IV)NC1 monomers, generally with considerably lower titers. Reactivity to alpha 3(IV)NC1 was partially blocked by Mab17, with comparable degrees of inhibition in both groups. Western blot analysis with the human NC1 domains revealed no differences in reactivity between the two groups. Thus, differences in antigen specificities of anti-GBM antibodies in sera with or without ANCA were not detected. The anti-GBM response in both situations is hypothesized to be driven by the same immunogen, which is probably derived from NC1 domains of endogenous Type IV collagen.


Subject(s)
Antibodies, Antineutrophil Cytoplasmic/analysis , Antibodies/analysis , Kidney Glomerulus/immunology , Adult , Aged , Aging/immunology , Animals , Antibodies/immunology , Antibodies, Antineutrophil Cytoplasmic/classification , Antibodies, Monoclonal/immunology , Antibody Specificity , Basement Membrane/immunology , Blotting, Western , Cattle , Collagen/chemistry , Collagen/immunology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Sex Characteristics
18.
J Leukoc Biol ; 61(1): 113-23, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9000544

ABSTRACT

Proteinase 3 (PR3) is a neutrophil serine protease stored in the azurophil granules of the promyelocyte and its successors. The protease has been identified as an autoantigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) occurring in patients with Wegener's granulomatosis. To characterize the biosynthesis and processing of human PR3 in a transgenic cellular model, cDNA encoding human pre-proproteinase 3 cloned from U-937 cells was transfected to the rat basophilic/mast cell line RBL-1 and the murine myeloblast-like cell line 32D c13. The stable expression of transgenic proteinase 3 was characterized by biosynthetic labeling, followed by immunoprecipitation, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and fluorography. After pulse labeling for 30 min two proforms of PR3 (32 and 35 kDa), differing in carbohydrate content but with protein cores of identical size, were demonstrated. Chase of the label resulted in a processed 32-kDa form clearly visible in RBL, but only faintly in 32D cells, probably indicating delayed intracellular transfer in the latter cell line. Partial digestion with N-glycosidase F showed that both potential N-glycosylation sites on PR3 were occupied and conversion of the oligosaccharide side chains into complex forms was demonstrated by acquisition of resistance to endoglycosidase H. Translocation of PR3 to granules was shown by subcellular fractionation and immunocytochemistry. Enzymatic activation of PR3 was suggested by affinity to diisopropylfluorophosphate and removal of an amino-terminal propeptide. Cells transfected with PR3 showed positive immunofluorescence for ANCA-containing sera from patients with Wegener's granulomatosis. Our results show that human PR3 transfected to RBL or 32D cells is synthesized as a 29-kDa protein core glycosylated on two distinct sites. Oligosaccharide trimming and proteolytic processing occur and the protein is targeted for granular storage in a form antigenic for ANCA.


Subject(s)
Serine Endopeptidases/biosynthesis , Animals , Antibodies, Antineutrophil Cytoplasmic/immunology , Carbohydrate Metabolism , Enzyme Activation , Genetic Vectors/genetics , Granulomatosis with Polyangiitis/immunology , Humans , Mice , Myeloblastin , Protein Processing, Post-Translational , Rats , Serine Endopeptidases/chemistry , Serine Endopeptidases/genetics , Serine Endopeptidases/immunology , Time Factors , Transfection , Tumor Cells, Cultured/metabolism
19.
Clin Exp Immunol ; 105(3): 504-10, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8809141

ABSTRACT

Autoantibodies to the non-collagenous (NC1) domain of the alpha 3(IV)-chain of type IV collagen are found in sera from patients with anti-GBM nephritis. These antibodies have been shown to be pathogenic. In this study the antibody specificity has been investigated in patients with Goodpasture's syndrome and from a patient with atypical anti-GBM antibodies, recognizing the alpha 1(IV)-chain only. Overlapping synthetic peptides, covering the complete NC1 domains of the alpha 1(IV)- and alpha 3(IV)-chains were used in sandwich ELISA and competitive ELISA. None of the Goodpasture sera showed reactivity to the synthetic peptides. However, antibodies from the patient with atypical anti-GBM antibodies recognized a 20 amino acid peptide from the alpha 1(IV)-chain. The reactive peptide was further narrowed down with glycine substitution of the different amino acids. We have localized the epitope to the four last C-terminal amino acids of the alpha 1(IV)-chain, with the sequence 1754-MRRT. The two arginine residues were found to be essential for antibody binding. Threonine is important, while methionine is of less importance. These four amino acids are also determined to be the smallest peptide that could inhibit the binding of the autoantibodies to the native alpha 1(IV)-chain. This study shows that overlapping peptides can be used to map linear epitopes. However, for conformational epitopes such as the Goodpasture epitope, other methods must be used. It would be prognostically important to know the fine specificity of anti-GBM antibodies, since the patient with anti-alpha 1(IV) antibodies had a mild disease, while the Goodpasture patients with anti-alpha 3(IV) antibodies had a rapidly progressive disease.


Subject(s)
Autoantibodies/chemistry , Epitope Mapping , Kidney Glomerulus/immunology , Peptide Fragments/chemistry , Peptide Fragments/immunology , Amino Acid Sequence , Amino Acids/analysis , Anti-Glomerular Basement Membrane Disease/immunology , Antibody Specificity , Basement Membrane/immunology , Collagen/immunology , Humans , Molecular Sequence Data , Peptide Fragments/chemical synthesis
20.
Kidney Int ; 46(3): 823-9, 1994 Sep.
Article in English | MEDLINE | ID: mdl-7527877

ABSTRACT

Goodpasture's syndrome is a life threatening autoimmune kidney disease. The patients have autoantibodies to the glomerular basement membrane, which are specific for the C-terminal domain of type IV collagen (NC1). The major antigen has been localized to the alpha 3 (IV)-chain. We have investigated sera from 44 patients with anti-NC1 antibodies. The quantity of antibodies to four different alpha(IV)-chains of type IV collagen was measured with direct ELISA. We used affinity chromatography to separate the antibodies and their specificities were studied with ELISA. The results show that about 1% of the patients total IgG are anti-NC1 antibodies and that 90% of these antibodies are specific for the alpha 3(IV)-chain. Antibodies to the other alpha(IV)-chains were found in 80% of the patients. Furthermore, affinity purified anti-alpha 3(IV) antibodies from one patient were inhibited by antibodies from the other patients, from 4 to 72%. The antibodies, from 39 of the patients, were inhibited by a monoclonal antibody against the alpha 3(IV)-chain. The results indicate that patients with Goodpasture's syndrome can have antibodies to most of the alpha(IV)-chains, while the majority of anti-NC1 antibodies are restricted to the alpha 3(IV)-chain. Moreover the number of epitopes seems to be limited and the majority of the antibodies from most patients are against one single epitope on the alpha 3(IV)-chain.


Subject(s)
Anti-Glomerular Basement Membrane Disease/immunology , Autoantibodies/analysis , Collagen/immunology , Kidney Glomerulus/immunology , Antibodies, Monoclonal , Antibody Specificity/immunology , Basement Membrane/immunology , Chromatography, Affinity , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Epitopes/immunology , Humans , Immunoglobulin G/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...